| Aug 24 |
Eli Lilly Alzheimer’s drug set to face same fate as Biogen’s in U.K.: report
|
| Aug 22 |
Biogen's Alzheimer's Drug Secures UK Approval, But An Independent Agency Does Not Recommend Reimbursement
|
| Aug 22 |
Biogen, Eisai new Alzheimer’s drug considered too costly in Britain
|
| Aug 22 |
Eisai’s Leqembi deemed too costly for NHS
|
| Aug 22 |
UK approves Leqembi, but reimbursement may not follow
|
| Aug 22 |
Biogen/Eisai’s Alzheimer's drug wins marketing nod in Great Britain
|
| Aug 22 |
Leqembi® (lecanemab) Authorized for Early Alzheimer's Disease in Great Britain
|
| Aug 20 |
Do Options Traders Know Something About Biogen (BIIB) Stock We Don't?
|
| Aug 17 |
Biogen: Q2 Earnings, Share Price May Have Bottomed Out As CEO Makes Mark
|
| Aug 15 |
Will Ionis' (IONS) Wholly-Owned Drugs Drive Future Growth?
|
